AIM: To evaluate the effects of intensive control of blood glucose and blood pressure on microvascular complications in patients with type II diabetes by comparing the therapeutic effects of intensive and standard treatment in patients with type II diabetes. METHODS: A total of 107 patients with type II diabetes were randomly assigned into intensive and standard treatment groups. Patients in the intensive treatment group received preterax (perindopril/ indapamide) to control blood pressure, and gliclazide (diamicron) MR to control blood glucose. Patients in the standard treatment group received routine medications or placebo. Urinary microalbumin (UMA), urinary creatinine (UCR), the UMA/UCR ratio, and visual acuity were monitored according to the study design of the ADVANCE trial. Direct ophthalmoscopy and seven-field stereoscopic retinal photography were used to examine the fundi at baseline, and repeated after 5 years of treatment. RESULTS: The characteristics of patients in both groups were well balanced at baseline. After 5 years of treatment, visual acuity was found to be decreased in the standard group (P=0.04), but remained stable in the intensive group. The severity of diabetic retinopathy had not progressed in patients in the intensive group, but had deteriorated in the standard group (P=0.0006). The UMA/UCR ratio was not obviously changed in patients in the intensive group, whereas it was significantly increased in the standard group (P=0.00). CONCLUSION:Intensive control of blood glucose and blood pressure can decrease the incidence or slow the progression of microvascular complications in patients with type II diabetes, and maintain stable vision.
RCT Entities:
AIM: To evaluate the effects of intensive control of blood glucose and blood pressure on microvascular complications in patients with type II diabetes by comparing the therapeutic effects of intensive and standard treatment in patients with type II diabetes. METHODS: A total of 107 patients with type II diabetes were randomly assigned into intensive and standard treatment groups. Patients in the intensive treatment group received preterax (perindopril/ indapamide) to control blood pressure, and gliclazide (diamicron) MR to control blood glucose. Patients in the standard treatment group received routine medications or placebo. Urinary microalbumin (UMA), urinary creatinine (UCR), the UMA/UCR ratio, and visual acuity were monitored according to the study design of the ADVANCE trial. Direct ophthalmoscopy and seven-field stereoscopic retinal photography were used to examine the fundi at baseline, and repeated after 5 years of treatment. RESULTS: The characteristics of patients in both groups were well balanced at baseline. After 5 years of treatment, visual acuity was found to be decreased in the standard group (P=0.04), but remained stable in the intensive group. The severity of diabetic retinopathy had not progressed in patients in the intensive group, but had deteriorated in the standard group (P=0.0006). The UMA/UCR ratio was not obviously changed in patients in the intensive group, whereas it was significantly increased in the standard group (P=0.00). CONCLUSION: Intensive control of blood glucose and blood pressure can decrease the incidence or slow the progression of microvascular complications in patients with type II diabetes, and maintain stable vision.
Authors: Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Emily Y Chew; Walter T Ambrosius; Matthew D Davis; Ronald P Danis; Sapna Gangaputra; Craig M Greven; Larry Hubbard; Barbara A Esser; James F Lovato; Letitia H Perdue; David C Goff; William C Cushman; Henry N Ginsberg; Marshall B Elam; Saul Genuth; Hertzel C Gerstein; Ulrich Schubart; Lawrence J Fine Journal: N Engl J Med Date: 2010-06-29 Impact factor: 91.245
Authors: Anushka Patel; S MacMahon; J Chalmers; B Neal; M Woodward; L Billot; S Harrap; N Poulter; M Marre; M Cooper; P Glasziou; D E Grobbee; P Hamet; S Heller; L S Liu; G Mancia; C E Mogensen; C Y Pan; A Rodgers; B Williams Journal: Lancet Date: 2007-09-08 Impact factor: 79.321
Authors: C P Wilkinson; Frederick L Ferris; Ronald E Klein; Paul P Lee; Carl David Agardh; Matthew Davis; Diana Dills; Anselm Kampik; R Pararajasegaram; Juan T Verdaguer Journal: Ophthalmology Date: 2003-09 Impact factor: 12.079
Authors: James W Albers; William H Herman; Rodica Pop-Busui; Eva L Feldman; Catherine L Martin; Patricia A Cleary; Barbara H Waberski; John M Lachin Journal: Diabetes Care Date: 2010-02-11 Impact factor: 19.112
Authors: J W J Beulens; A Patel; J R Vingerling; J K Cruickshank; A D Hughes; A Stanton; J Lu; S A McG Thom; D E Grobbee; R P Stolk Journal: Diabetologia Date: 2009-07-25 Impact factor: 10.122
Authors: Dana Lee Olstad; Reed Beall; Eldon Spackman; Sharlette Dunn; Lorraine L Lipscombe; Kienan Williams; Richard Oster; Sara Scott; Gabrielle L Zimmermann; Kerry A McBrien; Kieran J D Steer; Catherine B Chan; Sheila Tyminski; Seth Berkowitz; Alun L Edwards; Terry Saunders-Smith; Saania Tariq; Naomi Popeski; Laura White; Tyler Williamson; Mary L'Abbé; Kim D Raine; Sara Nejatinamini; Aruba Naser; Carlota Basualdo-Hammond; Colleen Norris; Petra O'Connell; Judy Seidel; Richard Lewanczuk; Jason Cabaj; David J T Campbell Journal: BMJ Open Date: 2022-02-15 Impact factor: 2.692
Authors: Bassirou A M Mounirou; Nouhou D Adam; Abba K H Yakoura; Mahamane S M Aminou; Yu T Liu; Li Y Tan Journal: Indian J Endocrinol Metab Date: 2022-06-06